查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1636006

2025-2033年按世代类型、抗癫痫药物类型、配销通路和地区分類的癫痫药物市场

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2024年全球癫痫药物IMARC Group规模达25亿美元。全球癫痫盛行率不断上升、药物开发和创新的显着进步、人们对癫痫及其治疗方案的认识不断提高、医疗保健支出不断增加和治疗机会的增加是推动市场成长的一些关键因素。

癫痫药物是指用于治疗癫痫的药物，癫痫是一种中枢神经系统 (CNS) 疾病，会导致不可预见的、无端的、反覆发作的癫痫发作。癫痫会影响各种精神和身体功能，导致突然的行为改变、感觉、意识丧失和严重的情绪困扰。其药物包括第一代、第二代和第三代抗癫痫药物 (AED)，例如透过口服、静脉注射 (IV) 和肌肉注射途径给药的片剂、胶囊、液体和糖浆。癫痫药物广泛用于治疗各种癫痫发作，包括局部性癫痫发作、难治性癫痫发作、混合性癫痫发作、强直阵挛性癫痫发作和急性反覆癫痫发作。癫痫药物是安全的，具有更好的耐受性，可以预防危及生命的不良反应，并最大限度地减少对认知功能的负面影响。

目前，由于神经系统疾病、产伤、感染、药物滥用和道路伤害发病率的增加，癫痫盛行率不断上升，这是推动市场成长的主要因素之一。癫痫药物广泛用于消除癫痫发作、减少癫痫发作频率、避免长期治疗的不良影响，从而帮助患者恢復正常的心理和职业活动，维持正常的生活方式。除此之外，容易罹患严重疾病（例如可能导致癫痫发作的脑癌）的老年人口数量不断增加，也是另一个主要的生长诱导因素。此外，广泛的研究和开发（R＆D）活动旨在开发新的和先进的药物，这些药物价格实惠，可提高耐受性和疗效，同时减少副作用，目前正在对市场成长产生积极影响。除此之外，最近开发的缓释（ER）药物配方允许更长的给药间隔，同时最大限度地减少血清药物水平的波动，从而与立即释放（IR）药物相比提高疗效和依从性，正在促进市场发展生长。此外，政府实施各种措施来教育大众了解这种疾病、促进研究并透过加速提供更好的治疗方案来提供积极支持，正在推动市场成长。其他因素，包括新药批准量的增加、医疗基础设施的快速改善、公众对神经系统疾病可用治疗方法的认识不断提高，以及与癫痫相关的耻辱感的减少，预计将推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球癫痫药物市场表现如何，未来几年将如何表现？
  • 全球癫痫药物市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球癫痫药物市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的癫痫药物市场？
  • 根据世代类型，市场的划分是怎么样的？
  • 癫痫药物市场中哪一代最有吸引力？
  • 根据抗癫痫药物类型，市场的细分如何？
  • 癫痫药物市场上最具吸引力的抗癫痫药物类型是什么？
  • 基于配销通路的市场区隔是什么？
  • 癫痫药物市场上最具吸引力的配销通路是哪一个？
  • 市场竞争结构如何？
  • 全球癫痫药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球癫痫药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按世代类型

  • 第一代药物
    • 市场趋势
    • 关键环节
      • 苯妥英
      • 卡马西平
      • 奥卡西平
      • 丙戊酸钠
      • 乙舒酰亚胺
      • 扑米酮
      • 苯巴比妥
    • 市场预测
  • 第二代药物
    • 市场趋势
    • 关键环节
      • 左乙拉西坦
      • 拉莫三嗪
      • 托吡酯
      • 普瑞巴林
      • 卢非酰胺
      • 唑尼沙胺
    • 市场预测
  • 第三代药物
    • 市场趋势
    • 关键环节
      • 拉科酰胺
      • 吡崙帕奈
      • 醋酸艾斯利卡西平
      • 埃佐加滨/瑞替加滨
    • 市场预测

第 7 章：市场细分：按抗癫痫药物类型

  • 窄谱 AED
    • 市场趋势
    • 市场预测
  • 广谱 AED
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 药局
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Alkem Laboratories Limited
    • Bausch Health Companies Inc.
    • Eisai Co. Ltd.
    • GSK plc
    • H. Lundbeck A/S
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Pfizer Inc.
    • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • UCB SA
Product Code: SR112025A6650

The global epilepsy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.87% during 2025-2033. The increasing prevalence of epilepsy worldwide, significant advancements in drug development and innovation, growing awareness about epilepsy and its treatment options, and rising healthcare expenditure and improving access to treatment are some of the key factors propelling the market growth.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
  • Competitive Landscape
  • The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global epilepsy drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global epilepsy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive epilepsy drugs market?
  • What is the breakup of the market based on the generation type?
  • Which is the most attractive generation type in the epilepsy drugs market?
  • What is the breakup of the market based on the anti-epileptics drugs type?
  • Which is the most attractive anti-epileptics drugs type in the epilepsy drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the epilepsy drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global epilepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Epilepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Generation Type

  • 6.1 First Generation Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Phenytoin
      • 6.1.2.2 Carbamazepine
      • 6.1.2.3 Oxcarbazepine
      • 6.1.2.4 Valproate
      • 6.1.2.5 Ethosuximide
      • 6.1.2.6 Primidone
      • 6.1.2.7 Phenobarbital
    • 6.1.3 Market Forecast
  • 6.2 Second Generation Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Levetiracetam
      • 6.2.2.2 Lamotrigine
      • 6.2.2.3 Topiramate
      • 6.2.2.4 Pregabalin
      • 6.2.2.5 Rufinamide
      • 6.2.2.6 Zonisamide
    • 6.2.3 Market Forecast
  • 6.3 Third Generation Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Lacosamide
      • 6.3.2.2 Perampanel
      • 6.3.2.3 Eslicarbazepine Acetate
      • 6.3.2.4 Ezogabine/Retigabine
    • 6.3.3 Market Forecast

7 Market Breakup by Anti-Epileptics Drugs Type

  • 7.1 Narrow-Spectrum AEDs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Broad-Spectrum AEDs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacy Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Alkem Laboratories Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch Health Companies Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 GSK plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 H. Lundbeck A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Jazz Pharmaceuticals plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 UCB S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List of Figures

  • Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2024
  • Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2024
  • Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2024
  • Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million USD), 2025-2033
  • Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million USD), 2025-2033
  • Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Epilepsy Drugs Market: Competitive Structure
  • Table 7: Global: Epilepsy Drugs Market: Key Players